Boston Therapeutics, Inc.
BTHE · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $9 | $9 | $7 | $1 |
| - Cash | $2 | $4 | $0 | $0 |
| + Debt | $1 | $3 | $1 | $5 |
| Enterprise Value | $7 | $8 | $8 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -1,434.8% |
| EBITDA | -$3,193 | -$3 | -$14 | -$0 |
| % Margin | – | – | – | -19,104% |
| Net Income | -$2,474 | -$4 | -$14 | -$0 |
| % Margin | – | – | – | -32,663.7% |
| EPS Diluted | -2.7 | -0.004 | -0.02 | -0.003 |
| % Growth | -69,130.8% | 80.8% | -534.4% | – |
| Operating Cash Flow | -$4 | -$1 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$1 | -$0 | -$0 |